Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Open access
Cobo-Calvo, Alvaro, Sepúlveda, María, Rollot, Fabien, Armangué, Thais, Ruiz, Anne, Maillart, Elisabeth, Papeix, Caroline, Audoin, Bertrand, Zephir, Helene, Biotti, Damien, Ciron, Jonathan, Durand-Dubief, Francoise, Collongues, Nicolas, Ayrignac, Xavier, Labauge, Pierre, Thouvenot, Eric, Bourre, Bertrand, Montcuquet, Alexis, Cohen, Mikael, Deschamps, Romain, Solà-Valls, Nuria, Llufriu, Sara, De Seze, Jerome, Blanco, Yolanda, Vukusic, Sandra, Saiz, Albert, Marignier, Romain · 2019 · Journal of Neuroinflammation

Abstract

BACKGROUND: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. METHODS: This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. RESULTS: Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. CONCLUSION: In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-019-1525-1

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 159

Metadata

Authors
Cobo-Calvo, A., Sepúlveda, M., Rollot, F., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., Ciron, J., Durand-Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Thouvenot, E., Bourre, B., Montcuquet, A., Cohen, M., Deschamps, R., Solà-Valls, N., Llufriu, S., De Seze, J., Blanco, Y., Vukusic, S., Saiz, A., & Marignier, R.
Venue
Journal of Neuroinflammation
Published
2019-07-02
Volume
16
Issue
1
Pages
134-134
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2953920705
Cited by
159
References
9
FWCI
14.55
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. https://app.cochat.ai/papers/10.1186/s12974-019-1525-1
The paper
Cobo-Calvo, A., Sepúlveda, M., Rollot, F., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., Ciron, J., Durand-Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Thouvenot, E., Bourre, B., Montcuquet, A., Cohen, M., . . . Marignier, R. (2019). Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-019-1525-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.